Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
[Abstract] J Chromatogr A
The SURMOUNT-1 trial showed that tirzepatide, a dual GIP/GLP-1 receptor agonist, produced even greater weight loss (up to 20.9% at the highest dose) with proportional reductions in waist circumference
The 28-day beyond-use date is a USP standard based on bacteriostatic efficacy studies at controlled refrigeration temperatures
METHOD DETAILS Sample preparation FOXO4 FHD (95-195) was subcloned into the pET His6 Tobacco Etch Virus (TEV) LIC cloning vector (2B-T, obtained from Scott Gradia, Addgene Plasmid #29666) and transformed into BL21 (DE3) cells
US$ 25.65
US$ 24.50
US$ 22.74
